Step away from the slide decks and join informal, peer-led discussion groups. Share experiences, debate novel methodologies, and benchmark strategies with your peers in an intimate, high-value networking environment.

• Defining regulatory expectations for non-invasive endpoint qualification provide greater clarity around evidence requirements, enabling more efficient biomarker and drug development
• Building fit-for-purpose evidence packages that align with evolving regulatory frameworks and support acceptance of non-invasive endpoints across multiple contexts of use
• Establishing clinically meaningful endpoints that can improve trial efficiency, reduce reliance on invasive procedures, and expand patient access to innovation